Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 09-23-2011, 01:07 PM   #1
Senior Member
Join Date: Aug 2006
Posts: 3,380
Denosumab Approved for Bone Loss From Hormone Ablation Therapy

Elsevier Global Medical News. 2011 Sept 19, E Mechcatie

The Prolia brand of denosumab has been approved as a treatment for bone loss in people receiving hormone ablation therapy for prostate or breast cancer, according to a statement from Amgen, the manufacturer.

The approved indications are for increasing bone mass in women at high risk for fracture on adjuvant aromatase inhibitor therapy for breast cancer and in men at high risk for fracture on androgen deprivation therapy (ADT) for nonmetastatic prostate cancer, the company's statement said.

Denosumab, a RANK ligand inhibitor, was first approved in June 2010 for treating postmenopausal women with osteoporosis at high risk of fracture and is marketed as Prolia for this indication. Prolia is administered in a subcutaneous injection once every 6 months, at a dose of 60 mg.

In November 2010, denosumab was also approved for preventing skeletal-related events in patients with bone metastases from solid tumors. It is marketed as Xgeva and administered more frequently at a higher dose for this indication.

Approval of the new indications for Prolia was based on phase III studies of these two groups of patients, according to Amgen. In an international study of almost 1,500 men with nonmetastatic prostate cancer who were being treated with ADT, bone mineral density at the lumbar spine after 2 years of treatment was significantly higher among men who had received denosumab compared with those who received placebo. After 3 years of treatment, the incidence of new vertebral fractures was 1.5% among those treated with denosumab, compared with 3.9% for those on placebo, a risk reduction of 62%, the company said.

And in a study of 252 postmenopausal women with breast cancer under treatment with an aromatase inhibitor, bone mineral density at the lumbar spine was significantly higher among those treated with denosumab compared with those on placebo after 12 months of treatment, according to the statement.

Arthralgia and back pain were the most common adverse events associated with treatment in these two groups of patients. Hypocalcemia was also reported; denosumab is contraindicated in people with hypocalcemia. Treatment was associated with cataract events in men in the prostate cancer trial.

In the European Union, denosumab is approved for the osteoporosis indication as well as the prostate cancer indication just approved in the United States, according to Amgen.

Hopeful is offline   Reply With Quote
Old 02-23-2012, 08:47 AM   #2
NewSurvivor's Avatar
Join Date: Sep 2011
Location: Panama City, Florida
Posts: 21
Re: Denosumab Approved for Bone Loss From Hormone Ablation Therapy

My doc started me on this Monday due to hip pain I have at night. Any one else taking this? And what is the favorite calcium supplement of the group?
July 2011
August 2011
Left Mastectomy
Axillary Sentinal Lymph Node Biopsy
Reconstruction w/ Tissue Expander
Stage 1, <2 cm, ER+/PR+, Her2+++
September 2011
Port placement 9/13/11
Chemo 9/19/11
Four Months Taxotere and Cytoxan
Chemo DONE 11/21/11!!!!
One Year Herceptin
January 2012
Started Femara 2.5MG 1/1/12
March 2012
Started Prolia Injection

Life is a Beautiful Mess
NewSurvivor is offline   Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 02:53 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter